Optometry - Journal of the American Optometric Association
Volume 75, Issue 7 , Pages 419-429, July 2004

Pediatric use of topical ophthalmic drugs

  • Rachel Anastasia Coulter, O.D.

      Affiliations

    • Corresponding Author InformationCorrespondence address: Nova Southeastern University 3200 South University Drive Ft. Lauderdale, Florida 33328.

Nova Southeastern University, College of Optometry, Ft Lauderdale, Florida

Article Outline

Background

Changes in the policies of the Food and Drug Administration (FDA) have resulted in a rapid increase in the number of drugs now labeled for pediatric use. In topical ophthalmic drugs, there are Pharmaceuticals approved for use in children in the treatment of allergy, inflammation, and bacterial and viral infection. Clinicians should anticipate that this trend will continue into the future.

Overview

This article reviews the history of FDA oversight of drugs used to treat children. Recent shifts in policies and approach are emphasized. Pediatric issues associated with ophthalmic drug use are discussed, including important differences regarding dosage, instillation, distribution, systemic toxicity, and metabolism. A summary of topical ophthalmic drugs approved for pediatric use, including age considerations, is provided.

Conclusions

Clinicians should be aware of the increasing number of topical ophthalmic drugs that are approved for pediatric use. Social, regulatory, and economic factors suggest this trend will continue. When prescribing these drugs for use in children, clinicians should remember to refer to details of labeling for Pediatric Use, including the age of the child for whom the drug is approved.

Key Words: Children, Food and Drug Administration (FDA), pediatric, topical ophthalmic drugs, treatment

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Cote CJ. Adverse drug reactions and the package insert. Acta Paediatr. 1999;88:925–927
  2. Nahata MC. (May 1997) Licensing of medicines for children in the USA. Paediatric and Perinatal Drug Therapy 1997. http://www.Priory.com/pharmol/lomfcitu.html. Last accessed April 3, 2002.
  3. Metry DW, Hebert AA. Topical therapies and medications in the pediatric patient. Pediatr Clin North Am. 2000;47(4):867–876
  4. Shelton DL. (June 12, 2000). Pace picks up in pediatric studies. Amednews.com. http://www.ama-assn.org/sci-pubs/amnews/pick_00/hlsa0612.html. Last accessed April 3, 2003.
  5. Modern regulatory environment shaped by pediatric pharmacology. Cited from Brown University Child and Adolescent Psychopharmacology Update 2002;4(5):l, 2-3. Medscape. http://www.medscape.com/viewarticle/433244_print. Last accessed April 4, 2003).
  6. Zenk KE. Challenges in providing pharmaceutical care to pediatric patients. Am J Hosp Pharm. 1994;51:688–694
  7. Meadows M. Drug research and children. FDA Consum. 2003;37(2):36
  8. Miller HI. The FDA drug approval process: focus on pediatric labeling [Letter to the editor]. Science. 2002;296(5573):1609–1610
  9. Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104:585–590
  10. Wilson JT, Kearns GL, Murphy D, et al. Paediatric labelling requirements: implications for pharmakinetic studies. Clin Pharmacokinet. 1994;24:308–325
  11. Turner ST, Longworth A, Nunn AJ, et al. Unlicensed and off label drug use in paediatric wards: prospective study. Br Med J. 1998;316:343–345
  12. Buck ML. (2000). The FDA Modernization Act of 1997: Impact on pediatric medicine. Cited from Pediatr Pharm 2000; 6(12):2000. Medscape. http://www.medscape.com/viewarticle/410910. Last accessed September 27, 2003.
  13. Bonetta L. Pediatric study of medicines becomes mandatory. Nat Med. 2000;6:1069
  14. Pediatric clinical trials are on the rise as new law goes into effect. (August 9, 2000). Medscape Medical News. http://www.medscape.com/viewarticle/412078. Last accessed September 28, 2003.
  15. Nordenberg T. Pediatric Drug Studies. FDA Consum. 1999;33(4):23–28
  16. Cohen SN. The pediatric pharmacology research unit (PPRU) network and its role in meeting pediatric labeling needs. Pediatrics. 1999;104:644–645
  17. Karst KR. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry. Am Univ Law Rev. 2000;49:739–772
  18. FDA draft sets 50,000 pediatric prescription mentions/year threshold for research list. FDC Reports “The Pink Sheet”1998;60(12):11-2.
  19. FDA mandatory pediatric labeling rule would apply to first indication for NMEs, marketed products with wide use or important benefits in children. FDC Reports “The Pink Sheet” 1997;59(33):3-4.
  20. HHS Identifies drugs for pediatric testing and announces FY 2003 and FY 2004 funding. News release (January 21, 2003) Health and Human Services, Washington, D.C. http://www.hhs.gov/news. Last accessed October 27, 2003.
  21. Dove A. FDA in a quandary over Pediatric Rule. Nat Med. 2002;8(6):541–542
  22. Safety-related labeling for pediatric drugs. Cited from Drug Benefit Trends 1999;11(1):11. Medscape. http://www.medscape.com/viewarticle/416823. Last accessed September 29, 2003.
  23. Otto A. Industry heeds FDA call to add pediatric info to drug labels. Cited from Pharmacy Today 2001. 7(2). Medscape. http://www.medscape.com/viewarticle/4066801. Last accessed September 29, 2003.
  24. Plummer J. (May 2000). FDA's Pediatric Rule restricts access to medicine. Consumers’ Research Magazine. www.consumeralert.org/pubs/research/CRMayOO.html. Last accessed April 3, 2003.
  25. Arshagouni P. (December 23, 2002). Federal court invalidates the FDA Pediatric Rule: AAPS v. FDA. http://www.law.uh.edu/healthlawperspectives/Children/021223Federal.html. Last accessed April 3, 2003.
  26. Association of American Physicians and Surgeons, Inc. v. U.S. Food and Drug Administration, 2002, U.S. Dist LEXIS 19689 http://www/law.uh.edu/healthlawperspectives (D.D.C., October 17, 2002).
  27. Barclay L. (November 6, 2002). Court overturns FDA Pediatric Rule: an expert interview with Philip Watson, M.D. Medscape Medical News, http://medscape.com/viewarticle/444180. Last accessed April 3, 2003.
  28. (2003). Recent court decision invalidating FDA's Pediatric Rule. Biotechnology Industry Organization, http://www.bio.org/reg/pedrule.asp. Last accessed April 3, 2003.
  29. Marshall E. Challenge to FDA's authority may end up giving it more. Science. 2002;296:820–821
  30. Best Pharmaceuticals for Children Act. Public Law 107–109. pll5 Stat. 1408.
  31. Pediatric Pharmacy Administrative Group Committee on Pediatric Pharmacy Practice. Am J Hosp Pharm. 1991;48:2475–2477
  32. Koren G, Barzilay , Greenwald M. Tenfold errors in administration of drug doses: a neglected iatrogenic disease in pediatrics. Pediatrics. 1986;177:848–849
  33. Jaanus SD. Pediatric pharmacology. In:  Rosenbloom AA,  Morgan MW editor. Principles and practice of pediatric optometry. Philadelphia: JB Lippincott Co; 1990;p. 293–312
  34. Mitchell A. (2001) Challenges in pediatric pharmacology: minimizing medication errors. Medscape Pharmacists 2 (10). http://www.medscape.com/viewarticle/421220. Last accessed September 28, 2003.
  35. The eye in childhood. Chicago: Yearbook Medical Publishers, Inc, 1967.
  36. In:  Liebman SD,  Gellis SS editor. Pediatric ophthalmology. St Louis: CV Mosby Co; 1966;
  37. Palmer EA. How safe are ocular drugs in pediatrics?. Ophthalmology. 1984;91:1361–1363
  38. Patton TF, Robinson JR. Pediatric considerations in ophthalmology. J Pediatr Ophthalmol. 1976;13:171–178
  39. Havener WH. Ocular pharmacology. 4th ed. St Louis: CV Mosby; 1978;218-61
  40. Abelson MB, Paradis A, Grant KK. How to prescribe for the smallest sufferers. Rev Ophthalmol. 1999;6(2):101–103
  41. Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. Trans Am Ophthalmol Soc. 1976;74:457–487
  42. Zimmerman TJ, Kooner KS, Kandarakis AS, et al. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102:551–553
  43. Barlett JD, Wesson MD, Swiatochoa , et al. Efficacy of a pediatric cycloplegic administration as a spray. J AM OPTOM ASSOC. 1993;64:617–621
  44. Ismail EE, Rouse MW, De Land PN. A comparison of drop instillation and spray application of 1% cyclopentolate. Optom Vis Sci. 1994;71:235–241
  45. Benavides JO, Satchell ER, Frantz KA. Efficacy of a mydriatic spray in the pediatric population. Optom Vis Sci. 1997;74:160–163
  46. Doe EA, Campagna JA. Pilocarpine spray: an alternative delivery method. J Ocul Pharmacol Ther. 1998;14:1–4
  47. Akman A, Aydin P. Comparison of mydriatic efficacy of spray instillation and drop instillation of tropicamide 1%. Eye. 1999;13:653–655
  48. Passo MS, Palmer EA, van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361–1363
  49. Nagataki S, Mishima S. Pharmacokinetics of instilled drugs in the human eye. Int Ophthalmol Clin. 1980;20(3):33–49
  50. Maurice DM. Factors influencing the penetration of topically applied drugs in the human eye. Int Ophthalmol Clin. 1980;20:21–32
  51. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 1982;26:207–218
  52. Chrai SS, Patton TF, Mehta A, et al. Lacrimal and instilled fluid dynamics in rabbit eyes. J Pharm Sci. 1973;62:1112–1121
  53. Brown RH, Hotchkiss ML, Davis EB. Creating smaller eyedrops by reducing eyedropper tip dimensions. Am J Ophthalmol. 1985;99:460–464
  54. Brown RH, Wood TS, Lynch MG, et al. Improving the therapeutic index of topical phenylephrine by reducing drop volume. Ophthalmology. 1987;94(7):847–850
  55. Lynch MG, Reay HB, Goode SM, et al. Reduction of phenylephrine size in infants achieves equal dilation with decreased systemic absorption. Arch Ophthalmol. 1987;105:1364–1365
  56. Wheatcroft S, Sharma A, McAllister J. Reduction in mydriatic drop size in premature infants. Br J Ophthalmol. 1993;77:364–365
  57. Walson PD, Getschman S, Koren G. Principles of drug prescribing in infants and children. A practical guide. Drugs. 1993;46(2):281–288
  58. Connor JD. A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule. Pediatrics. 1999;104(3):610–613
  59. Wilson RP. Lee DA, Netland PA, eds. The changing face of pediatric glaucomas. Rev Ophthalmol 2002;9(10):97-106.

PII: S1529-1839(04)70157-8

doi:10.1016/S1529-1839(04)70157-8

Optometry - Journal of the American Optometric Association
Volume 75, Issue 7 , Pages 419-429, July 2004

Article Tools